Abstract
Performance and cost of the best available analytical methodology for the measurement of aluminum in parenteral products are presented. Typical levels of aluminum in representative solutions are summarized. A methodical approach to the minimization of aluminum contamination in the manufacturing process is considered in light of aqueous aluminum chemical considerations. Results of long-term clinical follow-up studies of infants maintained on currently manufactured TPN solutions indicate no adverse pathology arising from aluminum.
- Received November 23, 1988.
- Accepted March 3, 1989.
- Copyright © Parenteral Drug Association. All rights reserved.
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.